Half-Year 2022 Financial and Clinical Trials Update

PRED immunology and ophthalmology development programs Molecule Indication Phase # of patients Status Immunology FPI Q4 2021 Ulcerative colitis lb 18 selnoflast (NLRP3i, RG6418) Recruitment completed Q2 2022 Chronic obstructive pulmonary disease lb 102 FPI Q2 2022 NME (RG6179)¹ VEGF-Ang2 DutaFab (RG6120) NME (RG7774) Partner: 1Sesen Bio DME Ophthalmology | 90 FPI Q3 2019 || 160 FPI Q4 2021 || 320 FPI Q4 2021 | ~50 FPI Q4 2020 = 135 FPI Q2 2020 nAMD Retinal disease || Roche CT Identifier DOVETAIL NCT05151744 (BARDENAS) NCT05151731 (ALLUVIUM) NCT04567303 NCT04265261 (CANBERRA) 154

View entire presentation